Organizing pneumonia in ALK+ non-small cell lung cancer treated with ceritinib: a case report

Abstract Introduction Anaplastic lymphoma kinase (ALK) inhibitors have been approved for non-small cell lung cancer (NSCLC) patients with ALK-rearrangement. Ceritinib, a clinically approved ALK inhibitor, is associated with some adverse reactions, including organizing pneumonia (OP). However, few ca...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xiao Lin, Mengyao Xie, Dandan Ma, Dandan Zheng, Jingjing Liu, Jinyan Ye, Lehe Yang, Yao Lu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Springer 2025-07-01
Edice:	Discover Oncology
Témata:	Ceritinib ALK +  Non-small cell lung cancer Organizing pneumonia Case report
On-line přístup:	https://doi.org/10.1007/s12672-025-02904-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!